Intracellular delivery of serum-derived hepatitis C virus

Takasuke Fukuhara, Hideki Tani, Mai Shiokawa, Yukinori Goto, Takayuki Abe, Akinobu Taketomi, Ken Shirabe, Yoshihiko Maehara, Yoshiharu Matsuura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A robust and reliable cell culture system for serum-derived HCV (HCVser) has not been established yet because of the presence of neutralizing antibody and tropism for infection. To overcome this obstacle, we employed a lipid-mediated protein intracellular delivery reagent (PIDR) that permits internalization of proteins into cells. Although entry of HCVcc was not enhanced by the treatment with PIDR, entry of HCVser into hepatoma cell lines (Huh7 and HepG2) and immortalized primary hepatocytes (Hc and HuS/E2) was significantly enhanced by the PIDR treatment. The entry of HCVser into Huh7 cells in the presence of PIDR was resistant to the neutralization by an anti-hCD81 antibody, suggesting that PIDR is capable of internalizing HCVser in a receptor-independent manner. Interestingly, the PIDR-mediated entry of HCVser and HCVcc was enhanced by the addition of sera from chronic hepatitis C patients but not from healthy donors. In addition, neutralization of HCVcc infection by anti-E2 antibody was canceled by the treatment with PIDR. In conclusion, the PIDR is a valuable tool to get over the obstacle of neutralizing antibodies to internalize HCV into cells and might be useful for the establishment of in vitro propagation HCVser.

Original languageEnglish
Pages (from-to)405-412
Number of pages8
JournalMicrobes and Infection
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 1 2011

Fingerprint

Hepacivirus
Serum
Proteins
Neutralizing Antibodies
Anti-Idiotypic Antibodies
Tropism
Chronic Hepatitis C
Infection
Hepatocytes
Hepatocellular Carcinoma
Therapeutics
Cell Culture Techniques
Tissue Donors
Lipids
Cell Line

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Infectious Diseases

Cite this

Fukuhara, T., Tani, H., Shiokawa, M., Goto, Y., Abe, T., Taketomi, A., ... Matsuura, Y. (2011). Intracellular delivery of serum-derived hepatitis C virus. Microbes and Infection, 13(4), 405-412. https://doi.org/10.1016/j.micinf.2011.01.005

Intracellular delivery of serum-derived hepatitis C virus. / Fukuhara, Takasuke; Tani, Hideki; Shiokawa, Mai; Goto, Yukinori; Abe, Takayuki; Taketomi, Akinobu; Shirabe, Ken; Maehara, Yoshihiko; Matsuura, Yoshiharu.

In: Microbes and Infection, Vol. 13, No. 4, 01.04.2011, p. 405-412.

Research output: Contribution to journalArticle

Fukuhara, T, Tani, H, Shiokawa, M, Goto, Y, Abe, T, Taketomi, A, Shirabe, K, Maehara, Y & Matsuura, Y 2011, 'Intracellular delivery of serum-derived hepatitis C virus', Microbes and Infection, vol. 13, no. 4, pp. 405-412. https://doi.org/10.1016/j.micinf.2011.01.005
Fukuhara T, Tani H, Shiokawa M, Goto Y, Abe T, Taketomi A et al. Intracellular delivery of serum-derived hepatitis C virus. Microbes and Infection. 2011 Apr 1;13(4):405-412. https://doi.org/10.1016/j.micinf.2011.01.005
Fukuhara, Takasuke ; Tani, Hideki ; Shiokawa, Mai ; Goto, Yukinori ; Abe, Takayuki ; Taketomi, Akinobu ; Shirabe, Ken ; Maehara, Yoshihiko ; Matsuura, Yoshiharu. / Intracellular delivery of serum-derived hepatitis C virus. In: Microbes and Infection. 2011 ; Vol. 13, No. 4. pp. 405-412.
@article{3b0e79aef6f64518b6eb60d1a9593e8e,
title = "Intracellular delivery of serum-derived hepatitis C virus",
abstract = "A robust and reliable cell culture system for serum-derived HCV (HCVser) has not been established yet because of the presence of neutralizing antibody and tropism for infection. To overcome this obstacle, we employed a lipid-mediated protein intracellular delivery reagent (PIDR) that permits internalization of proteins into cells. Although entry of HCVcc was not enhanced by the treatment with PIDR, entry of HCVser into hepatoma cell lines (Huh7 and HepG2) and immortalized primary hepatocytes (Hc and HuS/E2) was significantly enhanced by the PIDR treatment. The entry of HCVser into Huh7 cells in the presence of PIDR was resistant to the neutralization by an anti-hCD81 antibody, suggesting that PIDR is capable of internalizing HCVser in a receptor-independent manner. Interestingly, the PIDR-mediated entry of HCVser and HCVcc was enhanced by the addition of sera from chronic hepatitis C patients but not from healthy donors. In addition, neutralization of HCVcc infection by anti-E2 antibody was canceled by the treatment with PIDR. In conclusion, the PIDR is a valuable tool to get over the obstacle of neutralizing antibodies to internalize HCV into cells and might be useful for the establishment of in vitro propagation HCVser.",
author = "Takasuke Fukuhara and Hideki Tani and Mai Shiokawa and Yukinori Goto and Takayuki Abe and Akinobu Taketomi and Ken Shirabe and Yoshihiko Maehara and Yoshiharu Matsuura",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.micinf.2011.01.005",
language = "English",
volume = "13",
pages = "405--412",
journal = "Microbes and Infection",
issn = "1286-4579",
publisher = "Elsevier Masson SAS",
number = "4",

}

TY - JOUR

T1 - Intracellular delivery of serum-derived hepatitis C virus

AU - Fukuhara, Takasuke

AU - Tani, Hideki

AU - Shiokawa, Mai

AU - Goto, Yukinori

AU - Abe, Takayuki

AU - Taketomi, Akinobu

AU - Shirabe, Ken

AU - Maehara, Yoshihiko

AU - Matsuura, Yoshiharu

PY - 2011/4/1

Y1 - 2011/4/1

N2 - A robust and reliable cell culture system for serum-derived HCV (HCVser) has not been established yet because of the presence of neutralizing antibody and tropism for infection. To overcome this obstacle, we employed a lipid-mediated protein intracellular delivery reagent (PIDR) that permits internalization of proteins into cells. Although entry of HCVcc was not enhanced by the treatment with PIDR, entry of HCVser into hepatoma cell lines (Huh7 and HepG2) and immortalized primary hepatocytes (Hc and HuS/E2) was significantly enhanced by the PIDR treatment. The entry of HCVser into Huh7 cells in the presence of PIDR was resistant to the neutralization by an anti-hCD81 antibody, suggesting that PIDR is capable of internalizing HCVser in a receptor-independent manner. Interestingly, the PIDR-mediated entry of HCVser and HCVcc was enhanced by the addition of sera from chronic hepatitis C patients but not from healthy donors. In addition, neutralization of HCVcc infection by anti-E2 antibody was canceled by the treatment with PIDR. In conclusion, the PIDR is a valuable tool to get over the obstacle of neutralizing antibodies to internalize HCV into cells and might be useful for the establishment of in vitro propagation HCVser.

AB - A robust and reliable cell culture system for serum-derived HCV (HCVser) has not been established yet because of the presence of neutralizing antibody and tropism for infection. To overcome this obstacle, we employed a lipid-mediated protein intracellular delivery reagent (PIDR) that permits internalization of proteins into cells. Although entry of HCVcc was not enhanced by the treatment with PIDR, entry of HCVser into hepatoma cell lines (Huh7 and HepG2) and immortalized primary hepatocytes (Hc and HuS/E2) was significantly enhanced by the PIDR treatment. The entry of HCVser into Huh7 cells in the presence of PIDR was resistant to the neutralization by an anti-hCD81 antibody, suggesting that PIDR is capable of internalizing HCVser in a receptor-independent manner. Interestingly, the PIDR-mediated entry of HCVser and HCVcc was enhanced by the addition of sera from chronic hepatitis C patients but not from healthy donors. In addition, neutralization of HCVcc infection by anti-E2 antibody was canceled by the treatment with PIDR. In conclusion, the PIDR is a valuable tool to get over the obstacle of neutralizing antibodies to internalize HCV into cells and might be useful for the establishment of in vitro propagation HCVser.

UR - http://www.scopus.com/inward/record.url?scp=79952453062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952453062&partnerID=8YFLogxK

U2 - 10.1016/j.micinf.2011.01.005

DO - 10.1016/j.micinf.2011.01.005

M3 - Article

C2 - 21262370

AN - SCOPUS:79952453062

VL - 13

SP - 405

EP - 412

JO - Microbes and Infection

JF - Microbes and Infection

SN - 1286-4579

IS - 4

ER -